Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer (Q84976790)

From Wikidata

Jump to navigation Jump to search

scientific article published on 03 December 2009

Language	Label	Description	Also known as
English	Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer	scientific article published on 03 December 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Guru Sonpavde

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ana M Aparicio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Feng Zhan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Brittany North

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Robert Delaune

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Lawrence E Garbo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Steven R Rousey

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ralph E Weinstein

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Lianchun Xiao

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Kristi A Boehm

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Lina Asmar

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Mark T Fleming

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Matthew D Galsky

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

William R Berry

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Daniel D Von Hoff

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

3 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

682-689

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+Thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

DNA hypo-methylating agents and sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

The importance of careful blood processing in isolation of cell-free DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.09.015

7 January 2021

Identifiers

10.1016/J.UROLONC.2009.09.015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19959380%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84976790&oldid=1368858891"